Hanns-Christian Mahler is chief executive officer at ten23 health.

Prof. Dr. Hanns-Christian Mahler

Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.

How ten23 health is Advancing Patient-Centric Drug Delivery

CEO of the Year finalist at 2025 CPHI Pharma Awards, Prof. Dr. Mahler Hanns-Christian, who serves as CEO and co-founder of ten23 health, explains how ten23 health is helping shape the future of patient-centric drug delivery systems and the evolving expectations of modern CDMOs. He shares how industry limitations—particularly around flexibility, innovation, and patient-focused design—motivated him to co-found the company and build a new model for sterile drug product development and manufacturing.

Prof. Dr. Hanns-Christian comments on the growing demand for subcutaneous and self-injection therapies, highlighting why ease of use, patient comfort, and real-world administration are becoming central considerations in formulation and device design. He also explains how CDMOs can better support pharma partners by integrating delivery-system thinking early in development, strengthening supply chain reliability, and offering high-quality testing and sterile manufacturing capabilities at scale.

Sustainability is another major theme of the conversation. He outlines how next-generation CDMOs can embed responsible operations, energy efficiency, and waste reduction into everyday decision-making—advancing both environmental goals and long-term business resilience. 

Looking ahead, Prof. Dr. Hanns-Christian shares what excites him most about the future: expanded manufacturing capacity, continued innovation in patient-centric delivery, and new opportunities to elevate quality, reliability, and patient outcomes across the drug product lifecycle.

Videos

Blister packed medication in sterile hypodermic syringes | Image Credit - © kenwnj - © kenwnj - stock.adobe.com

In the dynamic landscape of pharmaceutical development, the management of modern sterile product developments has become an increasingly complex task, attributed to the evolving diversity of APIs. The landscape now encompasses a wide range of pharmaceutical entities, ranging from traditional small molecules to the forefront of biotechnological advancements including biologics (e.g., proteins, fusion proteins, bispecific antibodies, antibody-drug conjugates peptides, and nucleic acid-based therapeutics including oligonucleotides, RNA and DNA therapeutics, viral vectors, cell therapy, and more). Most of these later APIs are formulated as parenteral preparations, amplifying the unique multifaceted challenges associated in terms of formulation, manufacturing, administration, and regulatory considerations.

Managing the Complexity of Modern Sterile Product Developments

Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation

Andrea Allmendinger is chief science officer at ten23 health.
Hanns-Christian Mahler is chief executive officer at ten23 health.

When referring to this article, please cite it as Allmendinger, A; Mahler, H. Managing the Complexity of Modern Sterile Product Developments. 

Articles

Managing the intricacies of sterile product development is imperative for successful and compliant outcomes.